Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

An outline of technical considerations and production services for research-grade AAV9 vectors targeted for Central Nervous System (CNS) programs in the United Kingdom. The content details the production pathway, from plasmid services to purification and analytical release, and addresses the strategic importance of mitigating host immune responses for successful translation. All services are aligned with requirements for future Advanced Therapy Medicinal Product (ATMP) submissions to the MHRA.

The Technical Challenge of CNS Gene Delivery

Developing advanced therapies for neurological disorders requires a vector capable of efficiently transducing target cells within the CNS. AAV serotype 9 (AAV9) has demonstrated significant utility in this area, showing broad biodistribution throughout the brain and spinal cord. Its application in preclinical models has validated its potential to correct CNS pathology, providing a clear pathway for programs advancing toward clinical evaluation (PMID: 25027660).

Our team, which includes key scientific leadership from the former Penn Vector Core, has extensive experience producing high-titer, high-purity AAV9 vectors. This deep institutional knowledge of vector biology and manufacturing is applied to every project.

AAV9 Production: A Phased Approach

The manufacturing process for research-grade AAV9 is a multi-step workflow designed for quality and reproducibility. It begins with high-quality plasmid DNA and proceeds through transfection, packaging, and purification.

• Plasmid Services: We offer flexible DNA services, including amplification, characterization, and gene synthesis support to generate the necessary plasmid constructs.

• Transfection and Packaging: AAV9 vectors are produced via triple transfection of HEK293 cells, a well-established and scalable method.

• Purification and Titering: Particles are purified to the appropriate level for your research application. Accurate vector quantification is determined via digital droplet PCR.

Franklin Biolabs Facility Overview

Learn more about our >100,000 sq ft of specialized laboratory and animal housing space by viewing the full facility tour [here]).

Addressing Immunological Hurdles in CNS Therapy

A primary consideration for any AAV-based program is the potential for a host immune response against the vector capsid or the transgene product. Pre-existing or induced neutralizing antibodies can limit efficacy. Scientific literature suggests that neonatal vector administration can induce immunological tolerance, a strategy that improves outcomes of subsequent CNS-directed gene therapy by preventing antibody formation and enabling robust transgene expression (PMID: 26022732).

This insight informs our consultative approach. We work with sponsors to consider the complete preclinical strategy, ensuring the vectors we produce are suited for studies designed to minimize clinical risk and accelerate the 18-24 month timeline to IND.

Our collaborative approach combines deep technical expertise in vector production and analytics to deliver vectors that meet the stringent quality standards required for CNS research programs.

Our process, refined over extensive vector productions, provides the quality and consistency required to generate reliable data for your ATMP development program. This history of success is foundational to the Franklin Biolabs brand, which launched in 2024 to carry forward this legacy of scientific support.